

William A Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12116672/publications.pdf>

Version: 2024-02-01

24
papers

1,461
citations

471509

17
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

2340
citing authors

#	ARTICLE	IF	CITATIONS
1	Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac. <i>Acta Oncol</i> , 2022, 61, 111-115.	1.8	26
2	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2246-2256.	1.5	29
3	The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 124-128.	1.7	4
4	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. <i>Frontiers in Oncology</i> , 2021, 11, 628155.	2.8	27
5	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. <i>American Journal of Surgery</i> , 2021, 222, 10-17.	1.8	41
6	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	1.6	17
7	Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 271, 740-747.	4.2	127
8	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 235-242.	1.7	6
9	Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. <i>Surgery</i> , 2020, 168, 440-447.	1.9	15
10	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. <i>Practical Radiation Oncology</i> , 2020, 10, e495-e507.	2.1	50
11	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 460.	2.8	20
12	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. <i>Radiation Oncology</i> , 2019, 14, 114.	2.7	34
13	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. <i>Surgery</i> , 2019, 166, 277-285.	1.9	40
14	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332.	2.1	121
15	Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. <i>JAMA Oncology</i> , 2019, 5, 664.	7.1	40
16	A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 268, 610-619.	4.2	58
17	Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. <i>Cancer</i> , 2017, 123, 3486-3493.	4.1	103
18	Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2325-2332.	1.6	490

#	ARTICLE	IF	CITATIONS
19	Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 358.	2.0	12
20	CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer. <i>Cancer Research</i> , 2014, 74, 2677-2687.	0.9	34
21	Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. <i>Cancer</i> , 2014, 120, 499-506.	4.1	39
22	The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 77-85.	1.4	10
23	The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. <i>Cancer</i> , 2013, 119, 2350-2357.	4.1	13
24	Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. <i>Cancer</i> , 2013, 119, 3148-3155.	4.1	105